[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE69028775D1 - Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen - Google Patents

Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen

Info

Publication number
DE69028775D1
DE69028775D1 DE69028775T DE69028775T DE69028775D1 DE 69028775 D1 DE69028775 D1 DE 69028775D1 DE 69028775 T DE69028775 T DE 69028775T DE 69028775 T DE69028775 T DE 69028775T DE 69028775 D1 DE69028775 D1 DE 69028775D1
Authority
DE
Germany
Prior art keywords
thiazine
dyes
xanthene dyes
antiviral therapy
dye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE69028775T
Other languages
English (en)
Other versions
DE69028775T2 (de
Inventor
Raymond Schinazi
Robert Floyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26996594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69028775(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Application granted granted Critical
Publication of DE69028775D1 publication Critical patent/DE69028775D1/de
Publication of DE69028775T2 publication Critical patent/DE69028775T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69028775T 1989-05-11 1990-05-11 Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen Revoked DE69028775T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35038389A 1989-05-11 1989-05-11
US38900789A 1989-08-03 1989-08-03
PCT/US1990/002659 WO1990013296A1 (en) 1989-05-11 1990-05-11 Antiviral therapy using thiazine and xanthene dyes

Publications (2)

Publication Number Publication Date
DE69028775D1 true DE69028775D1 (de) 1996-11-07
DE69028775T2 DE69028775T2 (de) 1997-05-07

Family

ID=26996594

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69028775T Revoked DE69028775T2 (de) 1989-05-11 1990-05-11 Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen
DE199090909103T Pending DE471794T1 (de) 1989-05-11 1990-05-11 Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE199090909103T Pending DE471794T1 (de) 1989-05-11 1990-05-11 Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen.

Country Status (8)

Country Link
EP (1) EP0471794B1 (de)
JP (2) JPH07119173B2 (de)
AT (1) ATE143596T1 (de)
CA (1) CA2055463C (de)
DE (2) DE69028775T2 (de)
DK (1) DK0471794T3 (de)
ES (1) ES2032742T3 (de)
WO (1) WO1990013296A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6090043A (ja) * 1983-10-21 1985-05-21 Nippon Shokubai Kagaku Kogyo Co Ltd 窒素酸化物浄化用触媒
DE3930510A1 (de) * 1989-09-13 1991-03-21 Blutspendedienst Dt Rote Kreuz Verfahren zur inaktivierung von viren in blut und blutprodukten
US5545516A (en) * 1990-05-01 1996-08-13 The American National Red Cross Inactivation of extracellular enveloped viruses in blood and blood components by phenthiazin-5-ium dyes plus light
WO1991016911A1 (en) * 1990-05-01 1991-11-14 The American National Red Cross Decontamination of whole blood and cellular components by phenthiazin-5-ium-dyes plus light
US6207107B1 (en) 1992-10-05 2001-03-27 Baxter International Inc. Steam sterilizable system for inactivating viral contaminants in body fluids
US5660731A (en) * 1994-11-08 1997-08-26 Pall Corporation Filter for separating photoactive agent
AT406778B (de) * 1996-04-09 2000-09-25 Immuno Ag Verfahren zur desintegration von nucleinsäuren und herstellung von qualitätsgesicherten biologischen produkten
US5935581A (en) * 1996-07-24 1999-08-10 Kapadia; Govind J. Inhibitory effects of synthetic and natural colorants on carcinogenesis
US8974363B2 (en) 1997-12-11 2015-03-10 Provectus Pharmatech, Inc. Topical medicaments and methods for photodynamic treatment of disease
US6248733B1 (en) 1998-01-09 2001-06-19 3M Innovative Properties Company Method for limiting the growth of microorganisms using metal-containing compounds
US8557298B2 (en) 1998-08-06 2013-10-15 Provectus Pharmatech, Inc. Medicaments for chemotherapeutic treatment of disease
US6610436B1 (en) 1998-09-11 2003-08-26 Gore Enterprise Holdings Catalytic coatings and fuel cell electrodes and membrane electrode assemblies made therefrom
AU7057200A (en) 1999-08-13 2001-03-13 Photogen, Inc. Improved topical medicaments and methods for photodynamic treatment of disease
US6432396B1 (en) 2000-07-06 2002-08-13 3M Innovative Properties Company Limiting the presence of microorganisms using polymer-bound metal-containing compositions
CA2547556A1 (en) * 2003-11-28 2005-06-16 Photopharmica Limited Developments in biologically active methylene blue derivatives (2)
US20050192267A1 (en) * 2004-02-20 2005-09-01 Hofmann Robert F. Use of targeted oxidative therapeutic formulation in treatment of viral diseases
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
WO2006032879A2 (en) * 2004-09-23 2006-03-30 Wista Laboratories Ltd. Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc)
US20060188866A1 (en) * 2005-02-18 2006-08-24 Children's Hospital Oakland Research Institute Diaminophenothiazine compositions and uses thereof
FR2899088B1 (fr) * 2006-03-31 2008-06-27 Mauna Kea Technologies Soc Par "microscopie de fluorescence fibree a base de bleu de methylene."
WO2011137447A1 (en) 2010-04-30 2011-11-03 Prostetta Antiviral Inc. Antiviral compounds
EP2699241B1 (de) 2011-04-20 2016-07-27 Prosetta Antiviral Inc. Antivirale verbindungen
JP7512409B6 (ja) * 2020-03-26 2024-07-23 プロヴェクタス ファーマテック，インク． 腫瘍学及びウイルス学におけるハロゲン化キサンテンの新規の使用
US11938182B2 (en) 2020-03-26 2024-03-26 Provectus Pharmatech, Inc. Halogenated xanthenes as vaccine adjuvants

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA993795A (en) * 1970-12-10 1976-07-27 Richardson-Merrell (Canada) Ltd. Antiviral compositions containing bis-basic ethers and thioethers of xanthene and xanthen-9-ones and methods of treating viruses therewith
US4305390A (en) * 1975-11-28 1981-12-15 Massachusetts Institute Of Technology Method for generating oxygen in an excited electronic state and inactivation of microorganisms
DE3341001A1 (de) * 1983-11-12 1985-05-23 Krause, Hans Jürgen Nanopartikel aus bioabbaubarem, synthetischem material, verfahren zu deren herstellung und ihre anwendung

Also Published As

Publication number Publication date
EP0471794B1 (de) 1996-10-02
DK0471794T3 (da) 1996-11-18
DE69028775T2 (de) 1997-05-07
JP2700126B2 (ja) 1998-01-19
ES2032742T1 (es) 1993-03-01
CA2055463C (en) 1997-09-30
DE471794T1 (de) 1992-07-23
EP0471794A1 (de) 1992-02-26
JPH07119173B2 (ja) 1995-12-20
ATE143596T1 (de) 1996-10-15
CA2055463A1 (en) 1990-11-12
JPH04507403A (ja) 1992-12-24
EP0471794A4 (en) 1992-05-06
JPH08151327A (ja) 1996-06-11
WO1990013296A1 (en) 1990-11-15
ES2032742T3 (es) 1997-02-01

Similar Documents

Publication Publication Date Title
ATE143596T1 (de) Antivirale therapie unter verwendung von thiazin- und xanthenfarbstoffen
ATE146968T1 (de) Verwendung von funkionellen derivaten des interzellulär-adhäsions-moleküls icam-1 in einer antivirus-therapie
BR8705535A (pt) Polipeptideos derivados do gene de tegumento de virus de imunodeficiencia humana em celulas de insetos infectados por baculovirus
DE3773892D1 (de) Medizinische verwendung von nukleosiden.
PT89838A (pt) Processo para a preparacao de agente terapeutico susceptivel de formar um complexo com glicoproteina de involucro de virus de imunodeficiencia humana
DE69008664D1 (de) Bestrahlung von bluterzeugnissen.
DE3785717D1 (de) Mehrfach-pulsverfahren und geraet angewendet in der oximetrie.
DE68923035D1 (de) Nachweis von Lanthanid-markierte Nukleotide mittels zeitgelöster Fluorometrie.
ES2123048T3 (es) Analogos de nucleosidos antiviricos.
NO893504D0 (no) Fremgangsmaate for fremstilling av transdermalt anvendbarefarmasoeytiske preparater med steroliner og/eller spiroketaliner.
FI901879A0 (fi) Foerfarande foer producering av naturligt hiv-gp160.
NO880935D0 (no) Fremgangmsaate for paavisning av hiv eller annet virus med lignende klinisk virkning.
ATE59778T1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
DE3750756D1 (de) Ausführung von Fehlererkennung unter Verwendung eines ungebrauchten Modulo-m-Kodes.
DE3881270D1 (de) Verwendung von pyrrolidon-derivaten als antiamnetikum.
DK135588A (da) Inaktivering af hiv i proteinholdige oploesninger ved hjaelp af phenoler
IT1225262B (it) Metodo per la sensibilizzazione di piccoli animali all'infezione da virus dell'immunodeficienza umana (hiv)
ATE26267T1 (de) Pyrimidin-derivate, ausgestattet mit antiviraler wirkung.
SU782756A1 (ru) Рабочий орган дл фрезеровани пней
DE68912432D1 (de) Pharmazeutische Zusammensetzung, verwendbar bei der Behandlung von Herzgefässerkrankungen.
ATA264387A (de) Pharmazeutische verwendung von phenoxypentyloxy-3,4-dihydro-2h-1-benzopyranderivaten
ES2054935T3 (es) Actividad anti-vih de bu-3608.
ATA263987A (de) Pharmazeutische verwendung von phenoxypentyloxy-3,4-dihydro-2h-1-benzopyrander vaten
BR8506737A (pt) Valvula cardiaca biologica e processo de construcao
DK380889A (da) Dithiophosphor(phosphon)syreestere, deres fremstilling og anvendelse som midler til bekaempelse af skadelige organismer samt ved fremgangsmaaden anvendelige mellemprodukter

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: OKLAHOMA MEDICAL RESEARCH FOUNDATION, OKLAHOMA, OK

8331 Complete revocation